Skyrizi vs Cosentyx
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Skyrizi | US Cosentyx | |
|---|---|---|
| Generic name | risankizumab | secukinumab |
| Drug class | IL-23 Inhibitor (Biologic) | IL-17A Inhibitor (Biologic) |
| Treats | Plaque psoriasis, psoriatic arthritis, Crohn's disease | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | Novartis |
| Year approved | 2019 | 2015 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $480M | $160M |
| Common side effects | Respiratory infections, Headache, Fatigue, Injection site reactions | Respiratory infections, Inflammatory bowel disease, Fungal infections, Injection site reactions |
Frequently asked questions
Is Skyrizi or Cosentyx better?
Neither is universally "better." Skyrizi (risankizumab) and Cosentyx (secukinumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Skyrizi and Cosentyx?
Skyrizi is a IL-23 Inhibitor (Biologic) made by AbbVie, while Cosentyx is a IL-17A Inhibitor (Biologic) made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Skyrizi has the larger estimated TV advertising budget of the two.